Ciocca D R, Puy L A, Fasoli L C
Unidad de Histo-Patologia Endócrina, Centro Regional de Investigaciones Cientificas y Technologicas (CRICYT), Mendoza, Argentina.
Cancer Res. 1989 Aug 1;49(15):4298-304.
The presence of an estrogen-regulated protein with 24,000 molecular weight has been studied in 47 patients with endometrial carcinomas and in 29 patients with cervical carcinomas in order to correlate its presence with that of estrogen receptors (ERs) and progesterone receptors (PgRs). In the cytosol tumor samples the Mr 24,000 protein was detected by the Western blot technique using a monoclonal antibody (C11), while the presence of ER and PgR was studied by the one-point dextran-coated charcoal assay. In the tumor tissue sections immunohistochemistry was applied to detect Mr 24,000 protein, ER, and PgR; in these cases monoclonal antireceptor antibodies (H222 and mPRI) were used to localize the receptor proteins. In endometrial and endocervical adenocarcinomas the presence of Mr 24,000 protein correlated significantly with that of ER (P less than or equal to 0.05) in the cytosol samples; when the evaluation was performed in the tumor sections, the presence of Mr 24,000 protein correlated with that of ER (P less than or equal to 0.005) and PgR (P less than or equal to 0.05) as well. The study also showed that almost 70% of the well-differentiated adenocarcinomas had ER, PgR, and Mr 24,000 protein. In 25% of the endometrial adenocarcinomas examined the tumors were associated with normal, proliferative, and hyperplastic endometrium; in these cases the presence of ER, PgR, and Mr 24,000 protein was evaluated by immunohistochemistry in the malignant and nonmalignant endometrium. On the other hand, there was a lack of correlation between Mr 24,000 protein, ER, and PgR in the squamous carcinomas of the uterine cervix and in the endometrial adenocarcinomas with squamous cells. In most of these cases the tumors lacked ER and PgR although 80% of them contained the Mr 24,000 protein to a variable degree. It is suggested that Mr 24,000 protein is involved in growth and differentiation (the Mr 24,000 protein is a heat shock protein) and that the gene coding of this protein is under hormonal control only in those tissues where growth and differentiation are strongly hormonally controlled (breast and endometrium).
为了将一种分子量为24000的雌激素调节蛋白的存在情况与雌激素受体(ERs)和孕激素受体(PgRs)的存在情况相关联,我们对47例子宫内膜癌患者和29例宫颈癌患者进行了研究。在肿瘤细胞溶胶样本中,使用单克隆抗体(C11)通过蛋白质印迹技术检测分子量为24000的蛋白,而通过单点葡聚糖包被活性炭分析法研究ER和PgR的存在情况。在肿瘤组织切片中,应用免疫组织化学检测分子量为24000的蛋白、ER和PgR;在这些情况下,使用单克隆抗受体抗体(H222和mPRI)定位受体蛋白。在子宫内膜和宫颈腺癌的细胞溶胶样本中,分子量为24000的蛋白的存在与ER的存在显著相关(P≤0.05);当在肿瘤切片中进行评估时,分子量为24000的蛋白的存在也与ER(P≤0.005)和PgR(P≤0.05)的存在相关。研究还表明,几乎70%的高分化腺癌具有ER、PgR和分子量为24000的蛋白。在25%接受检查的子宫内膜腺癌中,肿瘤与正常、增殖性和增生性子宫内膜相关;在这些情况下,通过免疫组织化学在恶性和非恶性子宫内膜中评估ER、PgR和分子量为24000的蛋白的存在情况。另一方面,在子宫颈鳞状细胞癌和伴有鳞状细胞的子宫内膜腺癌中,分子量为24000的蛋白、ER和PgR之间缺乏相关性。在大多数这些病例中,肿瘤缺乏ER和PgR,尽管其中80%在不同程度上含有分子量为24000的蛋白。有人提出,分子量为24000的蛋白参与生长和分化(分子量为24000的蛋白是一种热休克蛋白),并且该蛋白的基因编码仅在那些生长和分化受到强烈激素控制的组织(乳腺和子宫内膜)中受激素控制。